Sloan Kettering, Hackensack form immunology collaboration

By The Science Advisory Board staff writers

June 5, 2020 -- Memorial Sloan Kettering and Hackensack Meridian Health have formed an immunology research collaboration to support cancer immunotherapy research.

Three projects were selected in 2020 for funding support over two years. The projects range from exploring the creation of cancer-targeted T cells within the thymus to the impact of gut microbiota in patients with multiple myeloma. They will also fund research into the impact of the gut microbiome on stem cell transplantation.

Through the joint venture, researchers can apply for funding to support their investigations. The partnership aims to explore the immune system in both the lab and the clinic and to speed the discovery of immunotherapies.

Alligator, Scandion pursue preclinical immunotherapies
Sweden-based Alligator Bioscience and Scandion Oncology inked an agreement to explore the antitumor efficacy of CD40 antibody mitazalimab in combination...
CSL Behring, Seattle Children's to develop gene therapies
CSL Behring, a biotechnology company, and Seattle Children's Research Institute announced that the organizations have entered a strategic alliance to...
EdiGene, Immunochina to develop CAR-T therapy
EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter